---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-086651"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2026-07-24T20:15:40+00:00"
generated_at: "2026-07-24T20:17:29.736642+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Acura receives $200K loan from AD Pharma; warns of possible shutdown without more funding by mid-August

## Summary
- New $200K loan from Abuse Deterrent Pharma increases principal to $10.9M, bearing 5.25% interest.
- Accrued interest ~$1.2M as of July 17, 2026; overdue amounts bear 7.5% interest.
- Without additional financing by mid-August 2026, company will scale back operations, furlough/lay off employees, or seek bankruptcy.
- Failure to secure funding could result in complete loss of shareholder value.
- Loan proceeds used for day-to-day operations; no assurance of further financing.

## SEC filing metadata
- accession: 0001104659-26-086651
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2026-07-24T20:15:40+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465926086651/0001104659-26-086651-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465926086651/tm2621293d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-086651
- JSON: https://secwatch.observer/filing/0001104659-26-086651.json
- Plain text: https://secwatch.observer/filing/0001104659-26-086651.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.